← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ceramedix Holding, Llc
New York, NY
$10,185,867
Total funding
2
Grants
Funding over time
peak $2.5M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,185,867 · 2
By mechanism
R44$5,962,255 · 1
N01$4,223,612 · 1
Investigators at Ceramedix Holding, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE$1,529,485
N01 · FY2023 · AI
DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE$1,427,108
N01 · FY2024 · AI
DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE$1,267,019
N01 · FY2025 · AI
Non-Clinical Pharmacology of CX-01$1,011,743
R44 · FY2023 · AI
Non-Clinical Pharmacology of CX-01$1,002,340
R44 · FY2024 · AI
Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$994,084
R44 · FY2020 · AI
Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$993,013
R44 · FY2018 · AI
Non-Clinical Pharmacology of CX-01$992,960
R44 · FY2025 · AI
Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$968,115
R44 · FY2019 · AI